Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway
Executive Summary
Biosimilar products are not intended to be stand-alone development programs, agency stresses, noting that early analytical data can allow for more targeted clinical trials later.
You may also be interested in...
Biosimilar Advisory Committees Will Focus Less On Clinical Data
FDA wants panels to look more closely at analytics in lesson learned from Zarxio meeting.
Biosimilar Sponsors Offer Advisory Committee Primer
Extrapolation, uncertainty could prove important when the Oncologic Drugs Advisory Committee considers Sandoz’s filgrastim biosimilar on Jan. 7.
Sandoz Neupogen Biosimilar Heads To ODAC; Cmte. May Be Students As Much As Advisors
January meeting date suggests FDA’s review of Sandoz’s abridged filgrastim application is on track, but Oncologic Drugs Advisory Committee could be challenged by differences between biosimilar and conventional BLA development.